| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04:05 | Up 152% in a year, guess which ASX All Ords silver share is leaping again on 'bonanza-grade' results | ||
| 04:05 | Why Megaport and Xero shares are making the headlines today with big moves | ||
| 03:35 | Why has this ASX copper stock surged to a new 12-month high? | ||
| 03:35 | Which Australian ETFs would be top buys this month? | ||
| 03:35 | Is the TechnologyOne share price an opportunity too good to pass up? | ||
| 03:35 | Why on earth is the Bapcor share price crashing 21% on Thursday? | ||
| 03:05 | Worley unveils new growth strategy and $300m buyback at Investor Day | ||
| 03:05 | Why Xero shares are falling despite a big jump in revenue | ||
| 03:05 | Why CSL shares could be one of the best buys on the ASX right now | ||
| 03:05 | This ASX resources service provider could almost double in value, Shaw and Partners says | ||
| 03:05 | Why I would buy CBA and DroneShield shares after selloffs this week | ||
| 02:35 | Up 44% in a year, ASX All Ords gold stock slips despite 330,000-ounce gold boost | ||
| 02:35 | ASX 200 stock crashes 12% on half-year results | ||
| 02:35 | The ageing Australia megatrend: 3 ASX shares built to benefit | ||
| 02:05 | GrainCorp shares: 1H26 profit drops but guidance stands | ||
| 02:05 | Synlait Milk CEO resigns - the latest in a line of executive departures | ||
| 02:05 | Air New Zealand flags sharp FY26 loss as rising fuel costs bite | ||
| 02:05 | Megaport secures $254 million in contracts, boosts ARR and outlook | ||
| 01:35 | Top broker just slapped a buy rating on this ASX oil share | ||
| 01:35 | Is the worst over for CSL shares after this week's sell-off? | ||
| 01:35 | Down 42% this year, is it time to jump into Life360 shares? | ||
| 01:35 | 3 superannuation decisions you'll regret in retirement | ||
| 01:35 | Xero FY26 result: Revenue surges 31% but profit dips due to Melio acquisition costs | ||
| 01:35 | Why I think this ASX dividend share with a 9.5% dividend yield is a buy | ||
| 01:05 | Broker says this ASX biotech stock could rocket 250% |